Skip to content
  1. Home
  2. Latest news
  3. What you need to know about Johnson & Johnson’s 2017 full-year earnings report
FINAL LEDE- What You Need to Know About Johnson & Johnson's 2017 Full-Year Earnings Report- Earnings Illustration 2

What you need to know about Johnson & Johnson’s 2017 full-year earnings report

See how the company’s consumer, pharmaceutical and medical devices businesses performed in 2017 in this breakdown of its latest annual earnings report.

Johnson & Johnson shared financial information this morning about its full-year performance in 2017.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 135,000 employees across the globe working every day to help change the trajectory of health for humanity.

For more details about the company’s 2017 results, and to read a message from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic packed with key stats.


2017 Full Year Earnings Report Infographic

Johnson & Johnson’s 2017 Earnings

Read the earnings press release, which includes full financial data for 2017.

Want to see more company earnings information? Find several years of Johnson & Johnson quarterly and full-year results here.

More from Johnson & Johnson

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.

What is lupus?

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.

This scientist develops targeted treatments for cancer—here’s what drives and inspires him

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.